Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLOG
Read on
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
Revised Annex 1 and the Focus on Microbial Control Strategies
The updates to EU Annex 1 added a great deal of emphasis on microbial control. By performing gap assessments and developing thorough, site-specific...
Building Velocity into Fill/Finish Timelines: Your Guide to Quality and Regulatory Success in the CDMO Space
Manufacturing capabilities need innovation proportional to those in therapeutics discovery. Choosing a CDMO partner with the technologies and...
The Stage-Gate Model: A Proven Approach to Streamline Biomanufacturing
As biopharma companies outsource more specialized activity to CDMOs, successful technology transfer becomes even more integral to project success. To...
Cell Therapy – What Does It Take To Become a Mainstream Option
While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1,000 ongoing clinical trials and...
